T cells

[Bone Marrow Transplantation] Further preclinical and clinical studies will explore defibrotide’s potential utility in a broader range of disorders resulting from endothelial cell activation and dysfunction.

[JW Therapeutics] JW Therapeutics announced that it has received the Investigational New Drug clearance from the National Medical Products Administration of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor T cell JWCAR129 in treating relapsed or refractory multiple myeloma.

[Communications Biology] The authors showed the importance of immune tolerance for idiosyncratic drug toxicity (IDT) onset and determine whether it was susceptible to a common IDT, HLA-B*57:01-mediated abacavir-induced hypersensitivity, using CD4+ T cell-depleted programmed death-1 receptor-deficient HLA-B*57:01 transgenic mice

[Anti-Cancer Drugs] Subcutaneous A549 lung cancer and murine Lewis lung carcinoma (LLC) models were constructed, which were further intravenously injected with platinum-based drugs or concomitant administrated with anti-PD-1 antibody and or anti-NKG2D antibody.

[Molecular Therapy] Investigators discuss the potential of engineered B cells as a cell therapy, the challenges involved in editing the Ig locus and the advances that are making this possible, and envision future directions for this emerging field of immune cell engineering.

[Communications Biology] Investigators identified a TLR4+ follicular helper T cell-like population present in the blood and expanded in synovial fluid.